Management of bronchiectasis

Drug and Therapeutics Bulletin

Volumn 41, Issue 12, 2003, Pages 91-95

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BECLOMETASONE; CARBOCISTEINE; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COLISTIMETHATE; DORNASE ALFA; FLUTICASONE; GENTAMICIN; IPRATROPIUM BROMIDE; MANNITOL; MONTELUKAST; OXYGEN; SODIUM CHLORIDE; THEOPHYLLINE; TOBRAMYCIN;

BLOOD VESSEL INJURY; BRONCHIECTASIS; BRONCHODILATATION; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG MEGADOSE; HEMOPTYSIS; HUMAN; INFLAMMATION; LUNG DISEASE; LUNG FUNCTION; LUNG INFECTION; MUCOCILIARY CLEARANCE; MUCUS SECRETION; PATIENT REFERRAL; PHYSIOTHERAPY; QUALITY OF LIFE; RECURRENT INFECTION; RESPIRATORY FAILURE; REVIEW; UNITED KINGDOM;

EID: 0346965984     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2003.411291     Document Type: Review

References (65)

1. Wilson R. Bronchiectasis. In: Gibson GJ et al (Eds). Respiratory Medicine Volume 2. Third edition. London: Elsevier Science Ltd, 2003.
2. Currie D. Differential diagnosis of cystic fibrosis bronchiectasis [online]. Dewsbury and District Hospital. Available: http://www.cysticfibrosismedicine.com/public/articles_text.asp?id=107 [Accessed 20 November 2003].
3. Cole P. Host-microbe relationships in chronic respiratory infection. Respir 1989; 55 (suppl 1): 5-8.
4. Mysliwiec V, Pine JS. Bronchiectasis: the 'other' obstructive lung disease. Postgrad Med 1999; 106: 123-31.
5. Pasteur MC et al. An investigation into causative factors in patents with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-84.
6. Armstrong P et al. Imaging of Diseases of the Chest Third edition. London: Mosby International Ltd, 2000.
7. Currie DC et al. Interpretation of bronchograms and chest radiographs in patients with chronic sputum production. Thorax 1987; 42: 278-84.
8. van der Bruggen-Bogaarts BA et al. Assessment of bronchiectasis: comparison of HRCT and spiral volumetric CT. J Comput Assist Tomogr 1996; 20: 15-9.
9. Grenier P et al. Bronchiectasis: assessment by thin-section CT. Radiology 1986; 161: 95-9.
10. Shah PL et al. Determinants of chronic infection with Staphylococcus aureus in patients with bronchiectasis. Eur Respir J 1999; 14: 1340-4.
11. Bush A et al. Primary ciliary dyskinesia: diagnosis and standards of care. Eur Respir J 1998; 12: 982-8.
12. Jain NK et al. Airway obstruction in bronchiectasis and its reversibility - a study of 38 patients. Indian J Chest Dis Allied Sci 1992; 34: 7-10.
13. Ellis DA et al. Present outlook in bronchiectasis: clinical and social study and review of factors influencing prognosis. Thorax 1981; 36: 659-64.
14. Department of Health. Adult immunisation update [online]. PL/CMO/2003/6. London: Department of Health, 2003. Available: http://www.doh.gov.uk/cmo/letters/cmo0306.htm [Accessed 20 November 2003].
15. Cochrane GM et al. Effects of sputum on pulmonary function. BMJ 1977; 2:1181-3.
16. O'Neill B et al. The current physiotherapy management of patients with bronchiectasis: a UK survey. Int J Clin Pract 2002; 56: 34-5.
17. Sutton PP et al, Assessment of percussion, vibratory-shaking and breathing exercises in chest physiotherapy. Eur J Respir Dis 1985; 66: 147-52.
18. Gallon A. Evaluation of chest percussion in the treatment of patients with copious sputum production. Respir Med 1991; 85: 45-51.
19. Hardy KA, Anderson BD. Noninvasive clearance of airway secretions. Respir Care Clin N Am 1996; 2: 323-45.
20. Cecins NM et al. The active cycle of breathing techniques - to tip or not to tip? Respir Med 1999; 93: 660-5.
21. Langenderfer B. Alternatives to percussion and postural drainage. A review of mucus clearance therapies: percussion and postural drainage, autogenic drainage, positive expiratory pressure, flutter valve, intrapulmonary percussive ventilation, and high-frequency chest compression with the ThAIRapy Vest. J Cardiopulm Rehabil 1998; 18: 283-9.
22. Hess DR. The evidence for secretion clearance techniques. Respir Care 2001; 46: 1276-93.
23. Thompson CS et al. Randomised crossover study of the Flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57: 446-8.
24. Sutton PP et al. Chest physiotherapy: a review. Eur J Respir Dis 1982; 63: 188-201.
25. Sutton PP et al. Assessment of the forced expiration technique, postural drainage and directed coughing in chest physiotherapy. Eur J Respir Dis 1983; 64: 62-8.
26. Thomas J et al. Chest physical therapy management of patients with cystic fibrosis. A meta-analysis. Am J Respir Crit Care Med 1995; 151: 846-50.
27. Hasani A et al. Regional lung clearance during cough and forced expiration technique (FET): effects of flow and viscoelasticity. Thorax 1994; 49: 557-61.
28. Giles DR et al. Short-term effects of postural drainage with clapping vs autogenic drainage on oxygen saturation and sputum recovery in patients with cystic fibrosis. Chest 1995; 108: 952-4.
29. Miller S et al. Chest physiotherapy in cystic fibrosis: a comparative study of autogenic drainage and the active cycle of breathing techniques with postural drainage. Thorax 1995; 50: 165-9.
30. Savci S et al. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. J Cardiopulmonary Rehabil 2000; 20: 37-43.
31. Lapin CD. "Conventional postural drainage and percussion. Is this still the gold standard?" - against. Pediatr Pulmon 1994; (suppl 10): 87-8.
32. Franco F et al. Short acting beta-2 agonists for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 18 October 2002].
33. Sheikh A et al. Long-acting beta-2-agonists for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 10 July 2001].
34. Hill SL et al. Short term response of patients with bronchiectasis to treatment with amoxycillin given in standard or high doses orally or by inhalation. Thorax 1986; 41: 559-65.
35. Angrill J et al. Bronchiectasis. Curr Opin Infect Dis 2001; 14: 193-7.
36. Banerjee D, Stableforth D. The treatment of respiratory Pseudomonas infection in cystic fibrosis. What drug and which way? Drugs 2000; 60: 1053-64.
37. Conway A. Home intravenous therapy for bronchiectasis patients. Nurs Times 1996; 92: 34-5.
38. Silverman E et al. Current management of bronchiectasis: review and 3 case studies. Heart Lung 2003; 32: 59-64.
39. Cabello H et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997; 10: 1137-44.
40. Stockley RA et al. Effect of antibiotic treatment on sputum elastase in bronchiectatic outpatients in a stable clinical state. Thorax 1984; 39: 414-9.
41. Chan CH et al. Mycobacteria as a cause of infective exacerbation in bronchiectasis. Postgrad Med J 1992; 68: 896-9.
42. Currie DC et al. Double-blind randomized study of prolonged higher-dose oral amoxycillin in purulent bronchiectasis. QJM 1990; 76: 799-816.
43. Kuhn RJ. Formulation of aerosolized therapeutics. Chest 2001; 120: 94S-8.
44. Joint Formulary Committee. British National Formulary. Edition 46. London: Royal Pharmaceutical Society of Great Britain and British Medical Association, September 2003.
45. Lin H-C et al. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis. Am J Respir Crit Care Med 1997; 155: 2024-9.
46. Barker AF et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-5.
47. TOBI 300mg/5mL Nebuliser Solution. Summary of product characteristics, UK. Chiron Corporation Ltd, January 2002.
48. Corless JA, Warburton CJ. Leukotriene receptor antagonists for non-cystic fibrosis bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 24 January 2000].
49. Crockett AJ et al. Mucolytics for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 10 October 2000].
50. Ram FS et al. Inhaled steroids for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 24 December 1999].
51. Lasserson T et al. Anticholinergic therapy for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 12 July 1999].
52. Lasserson T et al. Oral steroids for bronchiectasis (stable and acute exacerbations) (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 24 June 1999].
53. Steele K et al. Oral methyl-xanthines for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 25 January 2000].
54. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 11 September 2001].
55. O'Donnell AE et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. Chest 1998; 113: 1329-34.
56. British Thoracic Society Standards of Care Committee. Non-invasive ventilation in acute respiratory failure. Thorax 2002; 57: 192-211.
57. Benhamou D et al. Long-term efficiency of home nasal mask ventilation in patients with diffuse bronchiectasis and severe chronic respiratory failure. A case-control study. Chest 1997; 112: 1259-66.
58. Gacouin A et al. Long-term nasal intermittent positive pressure ventilation (NIPPV) in sixteen consecutive patients with bronchiectasis: a retrospective study. Eur Respir J 1996; 9: 1246-50.
59. Kutlay H et al. Surgical treatment in bronchiectasis: analysis of 166 patients. Eur J Cardiothorac Surg 2002; 21: 634-7.
60. Swanson KL et al. Bronchial artery embolisation: experience with 54 patients. Chest 2002; 121: 789-95.
61. Mazières J et al. Limited operation for severe multisegmental bilateral bronchiectasis. Ann Thorac Surg 2003; 75: 382-7.
62. Hasan A et al. Bilateral sequential lung transplantation for end stage septic lung disease. Thorax 1995; 50: 565-6.
63. Charman SC et al. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002; 21: 226-32.
64. Egan TM et al. Long term results of lung transplantation for cystic fibrosis. Eur J Cardiothorac Surg 2002; 22: 602-9.
65. Bradley J et al. Physical training for bronchiectasis (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. [Date of most recent substantive amendment 4 November 1999].